Experimental Drug Cuts Bladder Cancer Recurrence Risk 68% in Phase 3 Trial
Key Facts
CG Oncology on November 16, 2026, announced positive topline results from the Phase 3 PIVOT-006 trial, in which its experimental drug cretostimogene cut the risk of bladder cancer recurrence by 68% compared with the observation arm. The results showed a hazard ratio of 0.32, with a 95% confidence interval between 0.23 and 0.45 and a p-value below 0.0001. The study tested intravesical treatment after complete tumor resection in patients with intermediate-risk non-muscle-invasive bladder cancer and high-grade papillary Ta disease. The company said the improvement in recurrence-free survival was statistically significant and clinically meaningful. The results provide a basis for a potential regulatory pathway, while the drug remains investigational and its safety and efficacy have not been established by health authorities.
The trial included 367 patients at about 90 sites in the United States and Canada, and compared intravesical cretostimogene after complete resection with observation. The study covered a defined group of non-muscle-invasive disease cases, not all bladder cancer patients. Patient characteristics included recurrent low-grade Ta tumors within less than 12 months, solitary low-grade tumors larger than 3 cm, and multifocal low-grade Ta tumors. It also included solitary high-grade Ta tumors measuring no more than 3 cm, and low-grade T1 cases. The company said the trial results could expand the groups eligible to benefit from the drug if approved, alongside its data in high-risk BCG-unresponsive disease.
On safety, CG Oncology described the results as encouraging in terms of safety and tolerability, saying it had observed no treatment-related adverse events of Grade 3 or higher and no discontinuations due to related effects. The results come amid a development program that the company said had included more than 700 patients with non-muscle-invasive bladder cancer through November 6, 2026. But it stressed that cretostimogene is an investigational drug candidate and that its safety and efficacy have not been established by the U.S. Food and Drug Administration or any other health authority. According to the company, there are currently no FDA-approved adjuvant treatments for the target group, which it estimates at about 50,000 patients. These estimates and the description of the unmet treatment need remain part of the company's presentation of the opportunity it is pursuing.
Arthur Kwan, the company's chief executive, said CG Oncology is working to complete a biologics license application for patients with intermediate-risk disease and high-grade Ta tumors in the second quarter of 2027, based on PIVOT-006 data. That anticipated filing is separate from the initial application the company is working to expand for BCG-unresponsive disease. Based on feedback from the U.S. Food and Drug Administration, the company plans to add only high-grade papillary disease cases to that initial application and expects to complete its submission before the end of March 2027. The company had forecast in November that it would complete the initial application during the fourth quarter of 2026, and said 12-month follow-up data from the BOND-003 Cohort P and CORE-008 Cohort CX groups are expected in December 2026. These dates put two regulatory pathways and clinical follow-up data among the company's upcoming milestones.
The company is scheduled to present topline results from the PIVOT-006 trial in an oral presentation during late-breaking sessions at the annual meeting of the Society of Urologic Oncology on December 2, 2026. CG Oncology said the trial makes cretostimogene the first treatment candidate, in its description, to show a significant benefit in reducing recurrence in a pivotal Phase 3 trial among patients with intermediate-risk disease and high-grade Ta disease. The upcoming presentation offers an opportunity to provide details beyond the initial announcement, while any use of the drug remains contingent on establishing safety and efficacy and obtaining regulatory approvals. The company also links data from this trial to its broader program in BCG-unresponsive non-muscle-invasive disease. The upcoming filing dates, as announced by the company, remain targets rather than approvals already in place.